• Skip to main content
  • Skip to footer

Qu Biologics

  • Who We Are
    • Mission and Values
    • Team and Board
  • What We Do
    • Transformational Science
    • SSI Platform
    • SSI Pipeline
    • Publications
  • Current Clinical Trials
    • RESILIENCE Study
    • PERIOP-06 Study
  • News
    • In the Press
    • Events
  • Investors
  • Careers
  • Contact
Search
Close Search
Home Hero

Pipeline

Qu’s SSIs are uniquely positioned to treat and prevent cancer, chronic inflammatory diseases, and metabolic disease in a targeted organ.

Dr. Hal Gunn, CEO

SSI Pipeline: Advancing Clinical Programs Across Multiple Disease Areas

Therapeutic Area
SSI
Indication
Pre-clinical
Phase I
Phase II
Phase III
oncology
PERIOP-06 Study (RCT)
SSI
QBECO
Indication
Colon cancer
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBKPN
Indication
Lung Cancer
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBECO
Indication
Pancreatic cancer
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBECO
Indication
Ovarian Cancer
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBSAU
Indication
Melanoma
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBSAU
Indication
Breast Cancer
Pre-clinical
Phase I
Phase II
Phase III
immunosenescence
RESILIENCE Study (RCT)
SSI
QBKPN
Indication
Immunosenescence
Pre-clinical
Phase I
Phase II
Phase III
chronic inflammatory diseases
SSI
QBECO
Indication
Crohn's Disease (CD)
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBECO
Indication
Ulcerative Colitis (UC)
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBKPN
Indication
Chronic Obstructive Pulmonary Disease
Pre-clinical
Phase I
Phase II
Phase III
SSI
QBKPN
Indication
Asthma
Pre-clinical
Phase I
Phase II
Phase III

Near Term Value Driving Milestones

Qu Biologics is actively enrolling participants in two randomized, double-blind, placebo-controlled clinical studies in immunosenescence (immune dysfunction with aging) (n=72)—the RESILIENCE Study—and in patients with late-stage colon cancer undergoing section of liver metastases (n=115)—the PERIOP-06 Study—with transformational milestones anticipated in Q1 2025.

Logo Light
  • Who We Are
  • What We Do
  • Current Clinical Trials
  • News
  • Investors
  • Careers
  • Contact
  • 4475 Wayburne Drive, Suite 305 Burnaby, B.C., Canada, V5G 4X4
  • 604.734.1450
    info@qubiologics.com

dashicons-facebook-alt
dashicons-twitter
dashicons-linkedin
dashicons-youtube

© 2025 Qu Biologics Inc. All Rights Reserved
| Terms of Use | Privacy Policy